• 1
    Committee of Public Health Priorities to Reduce and Control Hypertension in the U.S. Population: A Population-based Policy and Systems Change Approach to Prevent and Control Hypertension. Institute of Medicine. Washington, D.C: The National Academies Press; 2010.
  • 2
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 3
    Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:14271431.
  • 4
    Gums JG, Lopez LM, Quay GP, et al. Comparative evaluation of enalapril and hydrochlorothiazide in elderly patients with mild to moderate hypertension. Drug Intell Clin Pharm. 1988;22:680684.
  • 5
    Johnson JA, et al. Pharmacogenomics of antihypertensive drugs: rational and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Am Heart J. 2009;157:442449.
  • 6
    Johnson JA, Gong Y, Bailey KR, et al. Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. Clin Pharmacol Therap. 2009;86:533539.
  • 7
    Sliwa K, Norton GR, Kone N, et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol. 2004;44:18251830.